Vertex(VRTX) Seeking Alpha·2025-03-03 23:41Company Overview - Vertex Pharmaceuticals finished 2024 in a strong position, achieving significant revenue growth, particularly in its cystic fibrosis (CF) franchise, which treated more patients globally [3]. - The company received approval for ALYFTREK, marking its fifth medicine approved for cystic fibrosis patients, and is currently in the process of launching this new treatment [3]. Future Priorities - In 2025, the company is focused on the launch of ALYFTREK and the ongoing global launch of CASGEVY for sickle cell disease and transfusion-dependent thalassemia (TDT) patients, with expectations for the program to gain momentum [4]. - Additionally, Vertex recently launched JOURNAVX, a non-opioid pain signal inhibitor for moderate to severe acute pain, following its approval on January 30, 2025 [4].